+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dyskinesia Market - Global Forecast 2026-2032- Product Image
Dyskinesia Market - Global Forecast 2026-2032- Product Image
New

Dyskinesia Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 185 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082614
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The dyskinesia market is evolving amid clinical complexity, rising therapeutic diversity, and pressing strategic considerations for senior decision-makers. This page provides a clear overview and actionable insights into current barriers, drivers, and opportunities within dyskinesia care, innovation, and commercialization strategies.

Market Snapshot: Dyskinesia Market Growth and Opportunities

The Dyskinesia Market grew from USD 3.66 billion in 2025 to USD 3.93 billion in 2026 and is projected to reach USD 6.10 billion by 2032, registering a CAGR of 7.55%. This growth is propelled by clinical heterogeneity, varied patient needs, and rapid adoption of neuromodulation, precision dosing, and rehabilitation strategies. Dynamic regional trends, evolving regulatory frameworks, and the integration of multidisciplinary care shape both opportunities and challenges for market leaders seeking sustainable impact.

Scope & Segmentation

  • Clinical Subtypes: Chorea, myoclonus, athetosis, dystonia-related dyskinesia, Parkinson’s dyskinesia, spasmodic torticollis, tardive dyskinesia.
  • Treatment Modalities: Non-pharmacological (behavioral therapy, physical therapy, rehabilitation), pharmacological (anticholinergics, dopamine modulators, GABA agonists, NMDA receptor antagonists, VMAT2 inhibitors), surgical (ablative surgery, deep brain stimulation).
  • Administration Routes: Intravenous, infusion-based, oral, subcutaneous, and transdermal solutions, each with specific formulation and adherence considerations.
  • Care Settings: Home care environments, hospitals (inpatient/outpatient), research institutes, specialty clinics, and long-term care facilities, each influencing access and ongoing management.
  • End-User Dynamics: Differences between home care, movement disorder centers, and specialty institutions drive distinct workflows and procurement behaviors.
  • Geographic Regions: Americas, Europe, Middle East & Africa (EMEA), and Asia-Pacific, each with unique infrastructure, reimbursement models, and adoption patterns.
  • Technologies: Neuromodulation devices, remote monitoring tools, digital integration platforms, and advanced pharmaceuticals powering new therapeutic pathways.

Key Takeaways for Senior Decision-Makers

  • The dyskinesia landscape is clinically diverse, demanding tailored engagement strategies and adaptive product design to address the variability across subtypes and care settings.
  • Technological innovation—particularly in neuromodulation and remote monitoring—supports early intervention, reduces care fragmentation, and is integral to operationalizing patient-centered care.
  • Adaptive regulatory policies are expediting device and pharmaceutical approvals, but present companies with new challenges regarding real-world evidence, procurement, and commercial adoption.
  • Supply chain resilience and manufacturing localization have moved to the forefront due to shifting tariff policies and an increased need for procurement agility across key markets.
  • Strategic collaboration between device manufacturers, pharmaceutical innovators, and rehabilitation providers unlocks bundled care pathways that can improve patient adherence and functional outcomes.
  • Regional divergence in reimbursement and infrastructure readiness requires a customized, evidence-driven approach to market entry and sustained access.

Tariff Impact on Supply Chains and Commercial Strategy

Recent tariff adjustments have significantly influenced supply chain structures and procurement models within the dyskinesia sector, particularly where imported neuromodulation hardware and critical pharmaceutical components are concerned. Companies with localized manufacturing have absorbed cost and lead time pressures more effectively, while others have diversified sourcing and secured additional logistics pathways to preserve margin and supply continuity.

Methodology & Data Sources

This analysis synthesizes primary interviews with stakeholders, comprehensive literature and regulatory review, and robust segment-level comparisons. All findings undergo triangulation, peer review, and sensitivity analysis to ensure reliable, actionable insights.

Dyskinesia Market: Why This Report Matters

  • Enables informed planning by equipping leaders with a multidimensional view of clinical, operational, and commercial drivers in dyskinesia care.
  • Highlights actionable segmentation and tariff intelligence essential for shaping R&D, supply chain, and market access strategies.
  • Supports strategic decisions on manufacturing resilience, regional entry, and evidence generation in a changing innovation environment.

Conclusion

Dyskinesia market leadership demands coordinated investment across clinical, operational, and digital domains. Stakeholders who proactively align evidence, supply resilience, and partnership models will effectively translate complex innovation into sustainable impact.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Dyskinesia Market, by Dyskinesia Type
8.1. Athetosis
8.2. Chorea
8.3. Dystonia-Related Dyskinesia
8.4. Myoclonic Dyskinesia
8.5. Parkinson’s Dyskinesia
8.6. Spasmodic Torticollis
8.7. Tardive Dyskinesia
9. Dyskinesia Market, by Treatment Type
9.1. Non-Pharmacological Approaches
9.1.1. Behavioral Therapy
9.1.2. Physical Therapy & Rehabilitation
9.2. Pharmacological Treatments
9.2.1. Anticholinergics
9.2.2. Dopamine Modulators
9.2.3. GABA Agonists
9.2.4. NMDA Receptor Antagonists
9.2.5. VMAT2 Inhibitors
9.3. Surgical Treatments
9.3.1. Ablative Surgery
9.3.2. Deep Brain Stimulation (DBS)
10. Dyskinesia Market, by Route of Administration
10.1. Intravenous (IV) & Infusion-Based
10.2. Oral
10.3. Subcutaneous
10.4. Transdermal
11. Dyskinesia Market, by Patient Care Settings
11.1. Home Care
11.2. Hospitals
11.3. Research Institutes
11.4. Specialty Clinics & Rehabilitation Centers
12. Dyskinesia Market, by End User
12.1. Homecare Settings
12.2. Hospitals & Clinics
12.2.1. Inpatient Services
12.2.2. Outpatient Services
12.3. Long-Term Care Facilities
12.4. Specialty Movement Disorder Centers
13. Dyskinesia Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Dyskinesia Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Dyskinesia Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Dyskinesia Market
17. China Dyskinesia Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. AbbVie Inc.
18.7. Addex Therapeutics Ltd.
18.8. Bukwang Pharmaceutical Co., Ltd
18.9. Clearmind Medicine Inc.
18.10. Ipsen Pharma SAS
18.11. IRLAB Therapeutics AB
18.12. Luye Pharma Group Ltd.
18.13. Medtronic PLC
18.14. Melior Pharmaceuticals
18.15. Mitsubishi Tanabe Pharma Corporation
18.16. Motac France Sarl
18.17. Neurocrine Biosciences, Inc.
18.18. Neurolixis Inc.
18.19. PharmaTher Holdings Ltd.
18.20. Prilenia Therapeutics B.V.
18.21. ReCode Therapeutics, Inc.
18.22. Serina Therapeutics, Inc.
18.23. SOM INNOVATION BIOTECH, SA
18.24. Supernus Pharmaceuticals, Inc.
18.25. Teva Pharmaceutical Industries Ltd.
18.26. Toray Industries, Inc.
18.27. Vistagen Therapeutics, Inc.
18.28. Voyager Therapeutics, Inc.
18.29. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL DYSKINESIA MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL DYSKINESIA MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DYSKINESIA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DYSKINESIA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DYSKINESIA MARKET SIZE, BY ATHETOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL DYSKINESIA MARKET SIZE, BY CHOREA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL DYSKINESIA MARKET SIZE, BY DYSTONIA-RELATED DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL DYSKINESIA MARKET SIZE, BY MYOCLONIC DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON’S DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON’S DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL DYSKINESIA MARKET SIZE, BY PARKINSON’S DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL DYSKINESIA MARKET SIZE, BY SPASMODIC TORTICOLLIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL DYSKINESIA MARKET SIZE, BY TARDIVE DYSKINESIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL DYSKINESIA MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL DYSKINESIA MARKET SIZE, BY PHYSICAL THERAPY & REHABILITATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL DYSKINESIA MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DYSKINESIA MARKET SIZE, BY DOPAMINE MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL DYSKINESIA MARKET SIZE, BY GABA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL DYSKINESIA MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL DYSKINESIA MARKET SIZE, BY VMAT2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL DYSKINESIA MARKET SIZE, BY ABLATIVE SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL DYSKINESIA MARKET SIZE, BY DEEP BRAIN STIMULATION (DBS), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL DYSKINESIA MARKET SIZE, BY INTRAVENOUS (IV) & INFUSION-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL DYSKINESIA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL DYSKINESIA MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL DYSKINESIA MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL DYSKINESIA MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL DYSKINESIA MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY CLINICS & REHABILITATION CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL DYSKINESIA MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL DYSKINESIA MARKET SIZE, BY INPATIENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL DYSKINESIA MARKET SIZE, BY INPATIENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL DYSKINESIA MARKET SIZE, BY INPATIENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL DYSKINESIA MARKET SIZE, BY OUTPATIENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL DYSKINESIA MARKET SIZE, BY OUTPATIENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL DYSKINESIA MARKET SIZE, BY OUTPATIENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL DYSKINESIA MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL DYSKINESIA MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL DYSKINESIA MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY MOVEMENT DISORDER CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY MOVEMENT DISORDER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL DYSKINESIA MARKET SIZE, BY SPECIALTY MOVEMENT DISORDER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL DYSKINESIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS DYSKINESIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 114. AMERICAS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 115. AMERICAS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 116. AMERICAS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 125. NORTH AMERICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 126. NORTH AMERICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 127. NORTH AMERICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. NORTH AMERICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 129. NORTH AMERICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 136. LATIN AMERICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 137. LATIN AMERICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. LATIN AMERICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 139. LATIN AMERICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. LATIN AMERICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 151. EUROPE DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. EUROPE DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 153. EUROPE DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 154. EUROPE DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 155. EUROPE DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 156. EUROPE DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 157. EUROPE DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. EUROPE DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 159. EUROPE DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. EUROPE DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 169. MIDDLE EAST DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 170. MIDDLE EAST DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 171. AFRICA DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. AFRICA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 173. AFRICA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 174. AFRICA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 175. AFRICA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 176. AFRICA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 177. AFRICA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. AFRICA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 179. AFRICA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. AFRICA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL DYSKINESIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. ASEAN DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. ASEAN DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 194. ASEAN DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 195. ASEAN DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 196. ASEAN DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 197. ASEAN DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 198. ASEAN DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. ASEAN DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 200. ASEAN DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. ASEAN DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 202. GCC DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 203. GCC DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 204. GCC DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 205. GCC DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 206. GCC DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 207. GCC DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 208. GCC DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. GCC DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 210. GCC DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. GCC DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 222. BRICS DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. BRICS DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 224. BRICS DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 225. BRICS DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 226. BRICS DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 227. BRICS DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 228. BRICS DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. BRICS DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 230. BRICS DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. BRICS DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 232. G7 DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 233. G7 DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 234. G7 DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 235. G7 DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 236. G7 DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 237. G7 DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 238. G7 DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. G7 DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 240. G7 DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 241. G7 DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 242. NATO DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 243. NATO DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 244. NATO DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 245. NATO DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 246. NATO DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 247. NATO DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 248. NATO DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 249. NATO DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 250. NATO DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 251. NATO DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 252. GLOBAL DYSKINESIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)
TABLE 263. CHINA DYSKINESIA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 264. CHINA DYSKINESIA MARKET SIZE, BY DYSKINESIA TYPE, 2018-2032 (USD MILLION)
TABLE 265. CHINA DYSKINESIA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 266. CHINA DYSKINESIA MARKET SIZE, BY NON-PHARMACOLOGICAL APPROACHES, 2018-2032 (USD MILLION)
TABLE 267. CHINA DYSKINESIA MARKET SIZE, BY PHARMACOLOGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 268. CHINA DYSKINESIA MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
TABLE 269. CHINA DYSKINESIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 270. CHINA DYSKINESIA MARKET SIZE, BY PATIENT CARE SETTINGS, 2018-2032 (USD MILLION)
TABLE 271. CHINA DYSKINESIA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 272. CHINA DYSKINESIA MARKET SIZE, BY HOSPITALS & CLINICS, 2018-2032 (USD MILLION)

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Addex Therapeutics Ltd.
  • Bukwang Pharmaceutical Co., Ltd
  • Clearmind Medicine Inc.
  • Ipsen Pharma SAS
  • IRLAB Therapeutics AB
  • Luye Pharma Group Ltd.
  • Medtronic PLC
  • Melior Pharmaceuticals
  • Mitsubishi Tanabe Pharma Corporation
  • Motac France Sarl
  • Neurocrine Biosciences, Inc.
  • Neurolixis Inc.
  • PharmaTher Holdings Ltd.
  • Prilenia Therapeutics B.V.
  • ReCode Therapeutics, Inc.
  • Serina Therapeutics, Inc.
  • SOM INNOVATION BIOTECH, SA
  • Supernus Pharmaceuticals, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Industries, Inc.
  • Vistagen Therapeutics, Inc.
  • Voyager Therapeutics, Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages185
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.93 Billion
Forecasted Market Value ( USD ) by 2032 $ 6.1 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Tardive Dyskinesia Treatment Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Tardive Dyskinesia Treatment Medicine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Dyskinesia- Pipeline Insight, 2025 - Product Image

Dyskinesia- Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Tardive Dyskinesia Treatment Market Report 2025 - Product Image

Tardive Dyskinesia Treatment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Tardive Dyskinesia Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region - Analysis and Forecast, 2025-2035 - Product Image

Tardive Dyskinesia Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Tardive Dyskinesia Therapeutics - Global Strategic Business Report - Product Image

Tardive Dyskinesia Therapeutics - Global Strategic Business Report

  • Report
  • 240 Pages
  • Global
From

About the Dyskinesia Market

Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression. The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms. Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.